全部 AG Scientific GoldBio rPeptide Cellagen haemtech cellsignal Usbio Tebu-Bio Cellgs Life Sensors Neuromics Fitzgerald BioVision meridian life science adi arp1 Avidity Promega Selleck Chemicals Xcess MoBiTec biosynth Gendepot 4adi Abcepta A-M system Anaspec Ancell Assaypro Boston Biochem celllabs eylabs Immunoway PelFreez-Bio ViGene VivanTechnologies abbomax Abeomics abfrontier ACROBiosystems GlycoTech wpiinc ApexBio ArcicZymes aristabiologicals AustralBiologicals Bimake BioAcademia BioAssay Systems bioline

全部 1 - 12000 12001 - 24000 24001 - 36000 36001 - 48000 48001 - 60000

以往抑郁症方向的前瞻性系列治疗性试验提示，超过 60% 的抑郁症（MDD）患者在治疗起初接受药物治疗时未取得明显收效，这一比例随后期治疗策略的更换呈现下降趋势，直至换用第四种药物进行治疗时，预期缓解率或可低至 10% 至 15%。难治性抑郁